ZURA BIO LTD
ZURANASDAQTrading Snapshot
- Day Range
- $5.71 β $5.83
- 52-Week Range
- $1.39 β $7.44
- Volume
- $3.15B
- Avg Volume
- $2.46B
- Shares Outstanding
- 95.0M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $45M
- Last Q Revenue
- $11M
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-0.75
- Dividend Yield
- β
Why Investors Own ZURA
- βHigh-growth profile β revenue up +40.6% YoY with expanding US Equity exposure.
- βHealthy economics β 26% gross margin and 29% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ZURA BIO LTD
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7RΞ± inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 23.53 percent decrease over losses of $(0.17) per share from the same
William Blair Starts Zura Bio (ZURA) at Outperform
Zura Bio Limited (NASDAQ:ZURA) is one of the 10 High Growth Stocks Insiders Are Buying. On July 8, 2026, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive βdifferentiated efficacyβ in two ongoing Phase 2 studies in [β¦]